Journal of Pathology and Translational Medicine

Original Article

Analysis of PAX8 immunohistochemistry in lung cancers: a meta-analysis: Jae Han Jeong, Nae Yu Kim, Jung-Soo Pyo; J Pathol Transl Med. 2020;54(4):300-309. Published online July 10, 2020; DOI: https://doi.org/10.4132/jptm.2020.06.08

4,108 View
129 Download
4 Web of Science
4 Crossref

Background
In this meta-analysis, we aimed to evaluate the PAX8 immunohistochemical expressions in primary lung cancers and metastatic cancers to the lung.
Methods
We identified and reviewed relevant articles from the PubMed databases. Ultimately, 18 articles were included in this meta-analysis. PAX8 expression rates were analyzed and compared between primary and metastatic lung cancers.
Results
The PAX8 expression rate in primary lung cancers was 0.042 (95% confidence interval [CI], 0.025 to 0.071). PAX8 expression rates of small cell (0.129; 95% CI, 0.022 to 0.496) and non-small cell carcinomas of the lung (0.037; 95% CI, 0.022 to 0.061) were significantly different (p=.049 in a meta-regression test). However, the PAX8 expression rates of adenocarcinoma (0.013; 95% CI, 0.006 to 0.031) and squamous cell carcinoma (0.040; 95% CI, 0.016 to 0.097) were not significantly different. PAX8 expression rates of metastatic carcinomas to the lung varied, ranging from 1.8% to 94.9%. Metastatic carcinomas from the lung to other organs had a PAX8 expression rate of 6.3%. The PAX8 expression rates of metastatic carcinomas from the female genital organs, kidneys, and thyroid gland to the lung were higher than those of other metastatic carcinomas.
Conclusions
Primary lung cancers had a low PAX8 expression rate regardless of tumor subtype. However, the PAX8 expression rates of metastatic carcinomas from the female genital organs, kidneys, and thyroid were significantly higher than those of primary lung cancers.

Citations

Citations to this article as recorded by

Prognostic value of PAX8 in small cell lung cancer
Fengyun Tao, Hangyan Zhu, Jiayun Xu, Yanan Guo, Xin Wang, Lei Shao, Deng Pan, Guosheng Li, Rong Fang
Heliyon.2024; 10(7): e28251. CrossRef
Cystic primary squamous cell carcinoma of the thyroid
Sakurako Harada‐Kagitani, Yusuke Kouchi, Yoshiki Shinomiya, Takuto Hiramoto, Tomoyuki Arai, Toyoyuki Hanazawa, Kiyotaka Onodera, Kaito Nakama, Takanori Aihara, Masayuki Ota, Jun‐Ichiro Ikeda, Takashi Kishimoto
Pathology International.2024;[Epub] CrossRef
Immunocytochemistry of effusions: Processing and commonly used immunomarkers
Vinod B. Shidham, Beata Janikowski
Cytojournal.2022; 19: 6. CrossRef
Significance analysis of PAX8 expression in endometrial carcinoma
Shan Hu, Hua Gan, Fengmei Yang
Medicine.2022; 101(42): e31159. CrossRef

Letter to the Editor

Response to Comment on “Prognostic Role of Claudin-1 Immunohistochemistry in Malignant Solid Tumors: A Meta-Analysis”: Jung-Soo Pyo, Nae Yu Kim, Won Jin Cho; J Pathol Transl Med. 2019;53(6):412-414. Published online November 1, 2019; DOI: https://doi.org/10.4132/jptm.2019.09.27

3,711 View
60 Download

PDF

Original Article

Prognostic Role of Claudin-1 Immunohistochemistry in Malignant Solid Tumors: A Meta-Analysis: Jung-Soo Pyo, Nae Yu Kim, Won Jin Cho; J Pathol Transl Med. 2019;53(3):173-179. Published online March 5, 2019; DOI: https://doi.org/10.4132/jptm.2019.02.03

5,945 View
158 Download
5 Web of Science
4 Crossref

Abstract PDF

Background
Although the correlation between low claudin-1 expression and worse prognosis has been reported, details on the prognostic implications of claudin-1 expression in various malignant tumors remain unclear. The present study aimed to elucidate the prognostic roles of claudin- 1 immunohistochemistry (IHC) in various malignant tumors through a meta-analysis.
Methods
The study included 2,792 patients from 22 eligible studies for assessment of the correlation between claudin-1 expression and survival rate in various malignant tumors. A subgroup analysis based on the specific tumor and evaluation criteria of claudin-1 IHC was conducted.
Results
Low claudin-1 expression was significantly correlated with worse overall survival (OS) (hazard ratio [HR], 1.851; 95% confidence interval [CI], 1.506 to 2.274) and disease-free survival (DFS) (HR, 2.028; 95% CI, 1.313 to 3.134) compared to high claudin-1 expression. Breast, colorectal, esophageal, gallbladder, head and neck, and lung cancers, but not cervical, liver or stomach cancers, were significantly correlated with worse OS. Breast, colorectal, esophageal, and thyroid cancers with low claudin-1 expression were associated with poorer DFS. In the lower cut-off subgroup (< 25.0%) with respect to claudin-1 IHC, low claudin-1 expression was significantly correlated with worse OS and DFS.
Conclusions
Taken together, low claudin-1 IHC expression is significantly correlated with worse survival in various malignant tumors. More detailed criteria for claudin-1 IHC expression in various malignant tumors are needed for application in daily practice.

Citations

Citations to this article as recorded by

The Significance of Relative Claudin Expression in Odontogenic Tumors
Ekarat Phattarataratip, Kraisorn Sappayatosok
Head and Neck Pathology.2020; 14(2): 480. CrossRef
Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer
Simon Kind, Franziska Büscheck, Doris Höflmayer, Claudia Hube-Magg, Martina Kluth, Maria Christina Tsourlakis, Stefan Steurer, Till S. Clauditz, Andreas M. Luebke, Eike Burandt, Waldemar Wilczak, Andrea Hinsch, David Dum, Sören Weidemann, Christoph Fraune
World Journal of Urology.2020; 38(9): 2185. CrossRef
Characterisation of endogenous Claudin‐1 expression, motility and susceptibility to hepatitis C virus in CRISPR knock‐in cells
Camille M.H. Clément, Maika S. Deffieu, Cristina M. Dorobantu, Thomas F. Baumert, Nilda Vanesa Ayala‐Nunez, Yves Mély, Philippe Ronde, Raphael Gaudin
Biology of the Cell.2020; 112(5): 140. CrossRef
Comment on “Prognostic Role of Claudin-1 Immunohistochemistry in Malignant Solid Tumors: A Meta-Analysis”
Bolin Wang, Yan Huang
Journal of Pathology and Translational Medicine.2019; 53(6): 411. CrossRef

First
Prev
Page of 1
Next
Last

Search